BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MorphoSys AG Release: AbD Serotec Secures Exclusive Worldwide Manufacturing License to Key Research Antibodies from VU University Medical Center


9/16/2010 2:40:04 PM

Martinsried/Munich, Germany, and Amsterdam, the Netherlands, September 16, 2010 - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its research and diagnostic antibodies unit AbD Serotec has signed a license agreement with VU University Medical Center (VUmc), which provides AbD Serotec with worldwide exclusive rights to commercialize a number of antibody clones for research applications. These include the world’s most widely used reagents for studying macrophage subsets in rats, the “ED series” of antibodies.

The antibodies are key reagents for studying various cell types and processes which play a central role in the innate immune system. The innate immune system forms an initial line of defense against diverse invading foreign pathogens and damaged or infected host cells. It acts through a variety of primitive and more advanced mechanisms, including the complement cascade, pattern recognition receptors, and macrophages to identify and target foreign intruders. In addition, it initiates the host’s adaptive immune response via antigen presentation by dendritic cells. The original paper on the ED antibodies is a key publication in the field being cited over 1,600 times.

“In line with our strategy to achieve a market-leading position in key focus areas, we have decided to further expand our offering in innate immunity research and take an exclusive manufacturing license for a range of ED antibody clones from the VU University Medical Center,” commented Dieter Feger, Head of AbD Serotec. “AbD Serotec already provides an extensive collection of antibodies for studying the activities and actions of the innate immune system, all manufactured to highest quality standards and guaranteed for use in important applications such as flow cytometry and western blotting.”

AbD Serotec has launched a new website area summarizing its offering of performance-guaranteed antibodies and reagents focused on macrophages and dendritic cells, toll-like receptors, pattern recognition receptors, natural killer cell markers and the complement cascade. For further information, visit http://www.abdserotec.com

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R) and RapMAT(R) are registered trademarks of MorphoSys AG.

About VU University Medical Center:

VU University Medical Center’s core business consists of patient care, scientific research, and education. Its focal areas in care and research are: cancer and the immune system, the brain, movement, vital functions and extramural care. Every year, 38,000 patients are admitted (some for day therapy), over 300,000 patients visit the outpatient clinic and 40,000 visit the Emergency Department. About 2,000 medical students receive an education. The results of scientific research are presented in about 2,000 scientific publications and reports each year, including about 100 PhD theses.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Lynne Chapman ANDREW LLOYD & ASSOCIATES http://www.ala.com lynne@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES